| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5624324 | Alzheimer's & Dementia | 2013 | 7 Pages |
Abstract
The utility of this paradigm as a potential assay for phase I proof-of-concept trials, targeting molecular mechanisms that are central to the encoding and consolidation of new learning, is discussed.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Colleen E. Jackson, Paul T. Maruff, Peter J. Snyder,